Tech Company Financing Transactions
Avenzo Therapeutics Funding Round
Avenzo Therapeutics, based in San Diego, secured $60 million from OrbiMed, SR One Capital Management and Deep Track Capital.
Transaction Overview
Company Name
Announced On
9/22/2025
Transaction Type
Venture Equity
Amount
$60,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to support the advancement of Avenzo's pipeline of potential best-in-class oncology drug candidates.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
12707 High Bluff Drive 200
San Diego, CA 92130
USA
San Diego, CA 92130
USA
Phone
Website
Email Address
Not Recorded
Overview
Avenzo Therapeutics is a clinical-stage biotechnology company co-founded in 2022 by Dr. Athena Countouriotis and Dr. Mohammad Hirmand. The company is building and advancing a pipeline of potential best-in-class oncology therapies that target cell cycle control to prevent the aberrant cell proliferation that drives many cancers.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Athena Countouriotis
Chief Financial Officer
Paolo Tombesi
Chief Medical Officer
Mohammad Hirmand
Vice President
Melissa Fitzgerald
Vice President
Ming Lu
Vice President
Minal Mehta
VP - Bus. Development
Scott Lipman
VP - General Counsel
Brian Sun
VP - Marketing
Carla Taub
VP - Operations
Melissa Holmes
VP - Regulatory Affairs
Naresh Nayyar
Browse more venture capital transactions:
Prev: 9/22/2025: Intelligo venture capital transaction
Next: 9/22/2025: Cardless venture capital transaction
Share this article
Where The Data Comes From
We record every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs